New Treatment More Than Doubles Survival for High Risk Childhood Leukemia, Child & Family Research Institute Study
ScienceDaily (Nov. 28, 2009) — Results of a phase two clinical trial published October 5th in the Journal of Clinical Oncology show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for children with a high risk type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).